CEACAM5

Country selector

International Australia Austria France Germany Iran Iraq Japan Jordan Lebanon Near East Phillipines Portugal South Africa Switzerland Syria United States

Antibody-Drug Conjugate (ADC)

CEACAM5

Carcinoembryonic antigen-related cell adhesion molecule 5 (CEACAM5) is a cell surface glycoprotein that is overexpressed on tumor cells and is associated with tumor differentiation, invasion, and metastasis.^1,2 While expression of CEACAM5 is high in several tumor types, such as gastric, colorectal, and pancreatic cancers, expression in normal epithelial tissues is low.^3,4 Thus, CEACAM5 presents a potential target for anticancer therapy.

M9140 – CEACAM5 ADC

M9140 is an investigational CEACAM5 ADC that is designed to deliver a cytotoxic topoisomerase 1 (TOP1) inhibitor payload to CEACAM5-expressing tumor cells.^5-7 The TOP1 inhibitor payload enters the nucleus and disrupts DNA replication and repair, thereby killing CEACAM5-expressing tumor cells.^5-7 The payload can also enter and kill neighboring tumor cells via a bystander effect.⁵

M9140 in Advanced Solid Tumors⁸ (NCT05464030)

M9140 monotherapy is being investigated in a Phase 1, multicenter, open-label, first-in-human study in patients with advanced solid tumors.

Learn more about ADCs

We are exploring next-generation linker and payload technologies platforms with the aim to develop "first-in-class and best-in-class" ADCs as monotherapy and combination therapy with DNA damage response inhibitors, targeted therapies or immune-checkpoint inhibitors.

This investigational compound has not been approved by any health authority. Safety and efficacy have not been established.

ADC, antibody drug conjugate; CEACAM5, carcinoembryonic antigen-related cell adhesion molecule 5; TOP1, topoisomerase 1.

Tchoupa TA, Schuhmacher T, Hauck CR. Signaling by epithelial members of the CEACAM family - mucosal docking sites for pathogenic bacteria. Cell Commun Signal. 2014;12:27.
Beauchemin N, Arabzadeh A. Carcinoembryonic antigen-related cell adhesion molecules (CEACAMs) in cancer progression and metastasis. Cancer Metastasis Rev. 2013;32(3-4):643-671.
Decary S, Berne P-F, Nicolazzi C, et al. Preclinical activity of SAR408701: a novel anti-CEACAM5-maytansinoid antibody-drug conjugate for the treatment of CEACAM5-positive epithelial tumors. Clin Cancer Res. 2020;26(24):6589-6599.
Boogerd LSF, Vuijk FA, Hoogstins CES, et al. Correlation between preoperative serum carcinoembryonic antigen levels and expression on pancreatic rectal cancer tissue. Biomark Cancer. 2017;9:1179299X17710016.
Abuhelwa Z, Alloghbi A, Nagasaka M. A comprehensive review on antibody-drug conjugates (ADCs) in the treatment landscape of non-small cell lung cancer (NSCLC). Cancer Treat Rev. 2022;106:102393.
Lambert JM, Berkenblit A. Antibody-drug conjugates for cancer treatment. Annu Rev Med. 2018;69:191-207.
Pommier Y. Topoisomerase I inhibitors: camptothecins and beyond. Nat Rev Cancer. 2006;6(10):789-802.
Anti-CEACAM5 ADC M9140 in Advanced Solid Tumors. ClinicalTrials.gov identifier: NCT05464030. Updated July 19, 2022. Accessed December 1, 2023. https://clinicaltrials.gov/ct2/show/NCT05464030

GL-MULO-00158 | January 2024

Connect with us

Find the Healthcare Business of Merck on:

GL-MULO-00155 | November 2023

Data Privacy Terms of use Legal Disclaimer Contact Us

By clicking this link, you are leaving MerckGroupOncology.com. Please, note that this link will take you to a website оn which different Privacy Policy and Conditions may apply. Merck accepts no responsibility for websites not controlled directly by us. Please check Privacy Policy and Conditions of the linked website.

Welcome to Merck Healthcare!

Help us direct you to the right information by selecting one of the following options:

CEACAM5

Antibody-Drug Conjugate (ADC)

CEACAM5

M9140 – CEACAM5 ADC

Clinical trials

M9140 in Advanced Solid Tumors8 (NCT05464030)

Abbreviations

References

Cookie Disclaimer

Welcome to Merck Healthcare!

M9140 in Advanced Solid Tumors⁸ (NCT05464030)